SavedAdd your journal

Journals / Medicine Science / 2019 / Cilt: 8 - Sayı: 4

Do androgen levels play a role in predicting complications of preeclampsia?

Ali Sami GURBUZ
Nuri DANİSMAN
Pages
875–880
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

No significant association was found between dehydroepiandrosterone sulfate levels and fetal/maternal complications.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Preeclampsia is a multisystem disorder characterized by new-onset hypertension and proteinuria after 20 weeks of gestation.
📊
Key Findings & Data:The association between androgens and hypertension has been demonstrated.
💡
Conclusion & Impact:No significant association was found between dehydroepiandrosterone sulfate levels and fetal/maternal complications.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Preeclampsia is a multisystem disorder characterized by new-onset hypertension and proteinuria after 20 weeks of gestation. The association between androgens and hypertension has been demonstrated. The purpose of this study was to determine the relationship between androgen levels and fetal and maternal complications in patients with preeclampsia. This study included 178 patients who were followed up with the diagnosis of preeclampsia and gave birth in High-Risk Pregnancy Clinic of Zekai Tahir Burak Women’s Health Research and Education Hospital. Androstenedione, dehydroepiandrosterone sulfate, total testosterone and free testosterone levels were measured by the Immulite 200 chemiluminescence method on the BioDPC Isodata 100 Series Gamma Counter in venous blood samples. Maternal complications and fetal complications were recorded. The relationship between these complications and androgen levels was examined. Free testosterone levels were significantly higher in those with a 1-min Apgar score <7 than in those with a 1-min Apgar score ≥7. Total testosterone levels were significantly lower in the preterm group than in the non-preterm group. Androstenedione levels were significantly higher in the IUGR group than in the non-IUGR group. Total testosterone levels were significantly lower in the fetal distress group than in the non-fetal distress group. Total testosterone and androstenedione levels were significantly higher in patients with increased AST and ALT levels. Total testosterone levels were significantly higher in the group with maternal complications than in the group without maternal complications. While higher total testosterone levels indicated maternal complications in preeclampsia, total testosterone levels were shown to be lower in those with preterm birth and fetal distress. Androstenedione levels were shown to be higher in those with IUGR and elevated liver enzyme levels. No significant association was found between dehydroepiandrosterone sulfate levels and fetal/maternal complications.

🔖

Cite This Article

GURBUZ, A. S., DANİSMAN, N. (2019). Do androgen levels play a role in predicting complications of preeclampsia?. Medicine Science, Cilt: 8 - Sayı: 4, 875–880. https://ajindex.com/articles/277604

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Brown MA, Lindheimer MD, de Swiet M, et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX–XIV. Sibai BM, Gordon T, Thom E, et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. The National Institute of Child Health and Human Development Network of Maternal–Fetal Medicine Units. Am J Obstet Gynecol. 1995;172:642–8. Duley L. Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. Br J Obstet Gynaecol. 1992;99:547-53.
  2. Perez-Sepulveda A, Torres MJ, Khoury M, Illanes SE. Innate immune system and preeclampsia. Front Immunol. 2014;26:244. 5 Redman CW, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol. 2010;63:534–543. 6 Hsu P, Santner-Nanan B, Dahlstrom JE, et al. Altered decidual DCSIGN+ Antigen-Presenting cells and impaired regulatory T-cell induction in Preeclampsia. Am J Pathol. 2012;94:2149–60. 7 Hertig A, Liere P, Chabbert-Buffet N, et al. Steroid profiling in preeclamptic women: evidence for aromatase deficiency. Am J Obstet Gynecol. 2010;477:e1–9. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy.Obstet Gynecol. 2013;122:1122-31.
  3. Al Khaja KA, Sequeira RP, Alkhaja AK, Damanhori AH. Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations. J Hypertens. 2014;32:454-63.
  4. Baker PJ, Ramey ER, Ramwell PW. Androgen-mediated sex differences of cardiovascular responses in rats. Am J Physiol. 1978;235:H242-6. Bachmann J, Feldmer M, Ganten U, Stock G, Ganten G. Sexual dimorphism of blood pressure: possible role of the renin-angiotensin system. J Steroid Biochem Mol Biol. 1991;40:511-5.
  5. Acromite MT, Mantzoros CS, Leach RE, et al. Androgens in preeclampsia. Am J Obstet Gynecol. 1999;180:60-3.
  6. Correa PJ, Palmeiro Y, Soto MJ, et al. Etiopathogenesis, prediction, and prevention of preeclampsia. Hypertens Pregnancy. 2016;35:280-94.
  7. Jobe SO, Tyler CT, Magness RR, Aberrant synthesis, metabolism, and plasma accumulation of circulating estrogens and estrogen metabolites in preeclampsi implications for vascular dysfunction, Hypertension. 2013;61:480–7.
  8. Berkane N, Liere P, Oudinet JP, et al.